Compare PDS & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDS | ABUS |
|---|---|---|
| Founded | 1951 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 918.1M | 884.7M |
| IPO Year | 1998 | 2008 |
| Metric | PDS | ABUS |
|---|---|---|
| Price | $96.30 | $4.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $114.50 | $5.00 |
| AVG Volume (30 Days) | 126.3K | ★ 2.2M |
| Earning Date | 04-22-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 13.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,171,000.00 |
| Revenue This Year | $6.09 | $125.30 |
| Revenue Next Year | $2.10 | N/A |
| P/E Ratio | $884.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $36.20 | $2.71 |
| 52 Week High | $97.13 | $5.10 |
| Indicator | PDS | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 72.77 | 43.73 |
| Support Level | $54.77 | $4.23 |
| Resistance Level | N/A | $4.76 |
| Average True Range (ATR) | 2.91 | 0.23 |
| MACD | 0.25 | -0.05 |
| Stochastic Oscillator | 92.55 | 6.25 |
Precision Drilling Corp is a provider of contract drilling and completion and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. Contract Drilling Services include drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale and repair of drilling equipment. Completion and Production Services include service rigs, oilfield equipment rental, and camp and catering services.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.